Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared an article he and colleagues authored on X:
“Just in Prostate Cancer and Prostatic Diseases Journal.
TP53, RB1, PTEN Â worse PFS and OS in patients with mHSPC treated with ADTi.
After ext validation in larger and prosp datasets can help in prognostication and guide MDM.”
Authors: Georges Gebrael et al.
